ES8104983A1 - Prescribed substance for thrombosis prevention and remedy - Google Patents

Prescribed substance for thrombosis prevention and remedy

Info

Publication number
ES8104983A1
ES8104983A1 ES480921A ES480921A ES8104983A1 ES 8104983 A1 ES8104983 A1 ES 8104983A1 ES 480921 A ES480921 A ES 480921A ES 480921 A ES480921 A ES 480921A ES 8104983 A1 ES8104983 A1 ES 8104983A1
Authority
ES
Spain
Prior art keywords
pharmaceutically acceptable
remedy
amides
esters
furthermore
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES480921A
Other languages
Spanish (es)
Other versions
ES480921A0 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB2357578A external-priority patent/GB1604554A/en
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of ES480921A0 publication Critical patent/ES480921A0/en
Publication of ES8104983A1 publication Critical patent/ES8104983A1/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C15/00—Butter; Butter preparations; Making thereof
    • A23C15/12—Butter preparations
    • A23C15/126—Butter containing a minority of vegetable oils; Enrichment of butter with fatty acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
    • A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
    • A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
    • A23D9/013—Other fatty acid esters, e.g. phosphatides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A pharmaceutical composition contains (all-Z)-5,8,11,14,17-eicosapentaenoic acid or one of its pharmaceutically acceptable salts, esters or amides and a pharmaceutically acceptable vehicle. The (all-Z)-5,8,11,14,17-eicosapentaenoic acid or its pharmaceutically acceptable salts, esters or amides can be used for the treatment or prophylaxis of thromboembolic states, to increase the bleeding time, dissolve or disperse thrombi or platelet aggregates which have already formed or to modify or prevent the adhesion of platelets to damaged tissue. They can furthermore be used to treat platelets in order to reduce their tendency to aggregation and/or to increase the rate of their separation from one another. They can furthermore be used as additive to blood in an extracorporeal circulation.
ES480921A 1978-05-26 1979-05-25 Prescribed substance for thrombosis prevention and remedy Expired ES8104983A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB2357478 1978-05-26
GB2357578A GB1604554A (en) 1978-05-26 1978-05-26 Pharmaceutical and food formulations

Publications (2)

Publication Number Publication Date
ES480921A0 ES480921A0 (en) 1981-05-16
ES8104983A1 true ES8104983A1 (en) 1981-05-16

Family

ID=26256599

Family Applications (1)

Application Number Title Priority Date Filing Date
ES480921A Expired ES8104983A1 (en) 1978-05-26 1979-05-25 Prescribed substance for thrombosis prevention and remedy

Country Status (13)

Country Link
JP (1) JPS5515444A (en)
AU (1) AU527784B2 (en)
CA (1) CA1151068A (en)
CH (1) CH644267A5 (en)
DE (1) DE2831507A1 (en)
ES (1) ES8104983A1 (en)
FR (1) FR2426461A1 (en)
IE (1) IE48287B1 (en)
IL (1) IL55227A (en)
IT (1) IT1116505B (en)
NL (1) NL191332C (en)
NZ (1) NZ187908A (en)
SE (1) SE448678B (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5735512A (en) * 1980-06-27 1982-02-26 Nippon Oil & Fats Co Ltd Preventive and remedy for thrombosis
JPS59172416A (en) * 1983-03-18 1984-09-29 Terumo Corp Fat transfusion solution
FR2548021B1 (en) * 1983-06-29 1986-02-28 Dick P R PROLONGED AND CONTINUOUS DERMAL PHARMACEUTICAL COMPOSITIONS BASED ON ESSENTIAL FATTY ACIDS
CA1239587A (en) * 1983-10-24 1988-07-26 David Rubin Combined fatty acid composition for lowering blood cholestrol and triglyceride levels
JPS60132916A (en) * 1983-12-21 1985-07-16 Nisshin Oil Mills Ltd:The Food or drug for preventing thrombosis
US4752618A (en) * 1984-07-12 1988-06-21 New England Deaconess Hospital Method of minimizing efects of infection through diet
JPH0748991B2 (en) * 1984-08-29 1995-05-31 日本油脂株式会社 Tube feeding composition
GB8710780D0 (en) * 1987-05-07 1987-06-10 Scras Opthalmological application of eicosapentaenoic acid
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US5922345A (en) * 1990-12-07 1999-07-13 Scotia Holdings Plc Nutrition
WO1993020717A2 (en) * 1992-04-13 1993-10-28 Research Corporation Technologies, Inc. Reducing gastrointestinal irritation in infant nutrition
NL9401743A (en) * 1994-10-20 1996-06-03 Prospa Bv Salts of amino alcohols and pharmaceutical formulations containing them.
DE19503993A1 (en) * 1995-02-08 1996-08-14 Johann Friedrich Dr Med Desaga Enteral product contg n-3-fatty acid or deriv and medium chain length tri:glyceride
DE10056351A1 (en) * 2000-11-14 2002-05-29 Weylandt Karsten Henrich Pharmaceutical preparation containing omega-3 fatty acids and other active substances e.g. an antiinflammatory, cyclooxygenase II inhibitor, 5-lipoxygenase inhibitor or platelet aggregation inhibitor
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
MX2011011538A (en) 2009-04-29 2012-06-13 Amarin Pharma Inc Stable pharmaceutical composition and methods of using same.
NZ720946A (en) 2009-04-29 2017-09-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
SI3318255T1 (en) 2009-06-15 2021-07-30 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating stroke in a subject on concomitant statin therapy
CA2775339C (en) 2009-09-23 2017-03-28 Amarin Corporation Plc Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
WO2013103958A1 (en) 2012-01-06 2013-07-11 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
MX2020013922A (en) 2012-06-29 2022-08-15 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of a cardiovascular event in a subject on statin therapy.
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
WO2014123484A1 (en) 2013-02-06 2014-08-14 Agency For Science, Technology And Research Methods For Reducing Aggregate Content In Protein Preparations
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
MA51766A (en) 2018-09-24 2020-12-16 Amarin Pharmaceuticals Ie Ltd METHODS OF REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN A SUBJECT

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE319677B (en) * 1965-03-27 1970-01-19 Sumitomo Chemical Co
FR2097036A1 (en) * 1970-07-29 1972-03-03 Sopharga Lab Lipids contg fatty acids - for treatment of atheroslerosis
GB1476624A (en) * 1973-05-30 1977-06-16 Cepbepe Tranquiliser medicaments
GB1580444A (en) * 1976-11-04 1980-12-03 Bio Oil Res Pharmaceutical compositions
JPS6257605A (en) * 1985-09-05 1987-03-13 Kaizuka Kazutoshi Method for extracting effective component from multiple-element mineral

Also Published As

Publication number Publication date
IT1116505B (en) 1986-02-10
AU3808478A (en) 1980-01-17
CH644267A5 (en) 1984-07-31
JPS5515444A (en) 1980-02-02
FR2426461A1 (en) 1979-12-21
NL191332C (en) 1995-06-01
IE791023L (en) 1979-11-26
CA1151068A (en) 1983-08-02
IE48287B1 (en) 1984-11-28
DE2831507A1 (en) 1979-11-29
SE7904570L (en) 1979-11-27
IL55227A0 (en) 1978-09-29
IL55227A (en) 1982-12-31
SE448678B (en) 1987-03-16
ES480921A0 (en) 1981-05-16
NZ187908A (en) 1984-05-31
NL7904144A (en) 1979-11-28
FR2426461B1 (en) 1983-02-11
AU527784B2 (en) 1983-03-24
DE2831507C2 (en) 1989-07-13
NL191332B (en) 1995-01-02
IT7947717A0 (en) 1979-01-19

Similar Documents

Publication Publication Date Title
ES8104983A1 (en) Prescribed substance for thrombosis prevention and remedy
FR2635263B1 (en)
GB229644A (en) A method of producing a substance adapted to tampon wounds
DE69019084D1 (en) Methods for preventing mold.
SE8402550L (en) N-SUBSTITUTED DERIDATIVES OF MORANOLINE
ATE73657T1 (en) USE OF GAMMA-LINOLENIC ACID AND RELATED COMPOUNDS IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF ENDOMETRIOSIS.
PT64840A (en) PROCESS FOR THE PREPARATION OF ARALQUILIC ESTERS OF 1,4-DIHYDRAPIRIDINOCARBOXILIC ACID WITH CORONARY AND ANTIHYPERTENSIVE EFFECT APPLICATION OF THE SAME FOR THE PREPARATION OF CORONARY AND ANTIHYPERTENSIVE PHARMACEUTICAL COMPOSITIONS AND APPLICATION OF SAID PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BLOOD LACIRCULATION DISEASES
DE3371866D1 (en) Medicine, mixed calcium salts of polymeric anionic carboxylic acids and/or their sulfuric acid esters, process for their preparation and their use
PT79648B (en) PROCESS FOR PREPARING PHARMACEUTICAL PREPARATIONS WITH SPECIAL 1,2-DIACYL-GLYCERO-3-PHOSPHOCHOLINES FOR THE TREATMENT OF DISEASES IN THE STOMACH-DARM AREA
ES438931A1 (en) Compositions for treatment of cardiovascular conditions associated with overproduction of catecholamines
DK0594770T3 (en) Ophthalmological mixtures
ATE12791T1 (en) SHORT CHAIN OLIGOSACCHARIDES WITH BIOLOGICAL PROPERTIES, PROCESSES FOR THEIR PRODUCTION AND THEIR USES AS MEDICINAL PRODUCTS.
KR930009612A (en) Method for preparing virus-free thrombin concentrate
DE301966T1 (en) METHOD FOR THE TREATMENT OF JOINT DEGREASING.
GB1297080A (en)
ATE142491T1 (en) AGENTS FOR THE TREATMENT OF ATOPIC ECZEMA AND OTHER INFLAMMATORY SKIN DISEASES
AT303012B (en) Process for the preparation of new racemic or optically active 1- (2'-nitrilophenoxy) -2-hydroxy-3-ethylaminopropane and its acid addition salts
JPS5731623A (en) Production of gamma-globulin for intravenous injection
FR2503149B1 (en) MERCAPTOACYL-CARNITIN ESTERS, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF, ESPECIALLY IN THE TREATMENT OF POISONING AND BURNS AND AS MUCOLYTIC AGENTS
JPS5753475A (en) Novel thiazolyl-2-oxamic acid derivative, manufacture and medicine containing same
FR2368280A1 (en) Aspirin and dipyridamole salt compsn. - having blood platelet aggregation inhibitory activity
US2120680A (en) Method of and pledget for the treatment of accessible hemorrhage with snake venom having blood coagulating properties in vitro
EP0219468A3 (en) 4-methoxy-isophthalic acid derivative having a pharmacological activity in thromboembolic disorders and a process for the preparation thereof
IE34728L (en) Treatment of migraine
JPS57108014A (en) Antithrombotic agent